ADVERTISEMENT
A lot of folks are looking ahead to 2024 and asking how to make it their best year financially.
But many of them have zero idea about the bubble they accidentally invested in. This bubble is going to burst soon. Getting out early could be the difference between big profits and dropping a socioeconomic class.
If you’re looking for the chance to add huge sums to your account in 2024 by ringing up one win after another… I recommend giving Jason Bodner’s 3-step plan a hard look.
You can find out about the scheduled cash bubble pop here
The Inside Track: Nuvectis
Shares of biopharmaceutical firm Nuvectis (NVCT) soared 200% after going public at $5 per share in 2022. Chris MacDonald noted at the time that the intriguing oncology company was an exciting bet on a novel cancer-beating therapy:
The company’s key drug candidates include NXP800, a clinical-stage HSF1 pathway inhibitor. This drug is undergoing a Phase 1 study in patients with advanced tumors. This drug, along with NXP900, a preclinical SRC/YES1 kinase inhibitor, are ones that have a more speculative growth trajectory, given their early-stage status.
Fast forward two years, and Nuvectis has seen a sudden string of good news. In February, the U.S. Food and Drug Administration (FDA) granted the NXP800 development program both Fast Track and Orphan Drug designations. The following month, Nuvectis would report positive preliminary data for its Phase 1b clinical trial.
Perhaps the best news has been a recent $50,000 share purchase made by CEO & Chairman Ron Bentsur four days after the Phase 1b results were announced. On March 18, the 10% owner added 5,000 shares to his existing 3.2 million stake.
That’s an incredibly bullish sign. The company’s Phase 1b trials only included four patients, and the preliminary data is scant at best; only insiders like Bentsur would have full knowledge of efficacy. And the fact that he's adding even more to his already sizable stake suggests Bentsur knows something that markets do not.
That tells us that Nuvectis could be worth a small wager. I’ve found other 10x biotech winners before based on these types of insider buys, and Nuvectis looks much like these past bets.
The Biggest Winner: Eli Lilly
In January, my MarketMasterAI stock-picking system ranked Eli Lilly & Co. (LLY) as the top healthcare company to buy. The pharmaceutical giant came in seventh place overall.
Since then, shares of the Indiana-based firm have risen 30% on growing excitement over its GLP-1 weight loss drugs, Zepbound and Mounjaro. Sales of the latter already exceeded $5 billion in 2023, and demand is so red-hot that shortages are expected throughout 2024.
Last Sunday, Dmytro Spilka writes that Eli Lilly might now become the world’s first trillion-dollar pharmaceutical company . Zepbound, which was made available in December, recorded $175.8 million in sales within a month, smashing through analysts expectations of $75 million. And if profits continue rising at their current rate, Eli Lilly could reach that milestone as soon as this year.
Muslim Farooque goes even further and plainly calls Eli Lilly a name that could make you filthy rich.
A look at its spectacular Q4 results shows the incredible impact of its anti-obesity drugs on its top-line results. Q4 sales were at $9.35 billion, an extraordinary 28% increase YOY. Its anti-obesity offering in Mounjaro contributed $2.2 billion during the quarter, representing about 25% of total sales. Moreover, Zepbound, its latest weight-loss injection, generated $175.8 million in its debut quarter, with more growth expected ahead.
In short, Eli Lilly and its competitor Novo Nordisk (NVO) are sitting on a type of therapy that comes around only once every couple of generations. Around two-fifths of adults are overweight or obese globally, and that figure is as high as 60% in developed countries. Not only does this “miracle weight loss drug” work well – its market is absolutely enormous.
ADVERTISEMENT
CBDCs are government-backed digital currencies.
CBDCs are here to replace hard money, and…
CBDCs are under such incredible momentum that traditional money could soon vanish.
How much longer will paper currencies survive?
One top analyst says, “they could be dead within weeks.”
Click here for the full story
A Big Bet: Schrodinger
Alex Sirois flags Schrodinger (SDGR) as a stock to buy. The software research firm is part biotech stock and part AI stock.
In order to develop a therapeutic, biotechnology firms first have to identify molecules that have the potential to treat a target disease. It’s a painstaking process that is becoming easier through the use of computers, machine learning, and artificial intelligence.
Schrodinger has emerged as a leading name in that space. The company essentially does two things. One, it licenses its technology to firms wishing to discover molecules with treatment potential. Two, the company is also currently building a portfolio of clinical and preclinical programs.
Schrodinger has seen significant real-world success. Sirois notes that Q4 revenues grew by more than 30%, and that Schrodinger itself maintains an ability to produce a blockbuster drug of its own. Advances in AI computing power also gives the chemical simulation firm a new edge.
Of course, Schrodinger isn’t the only company involved in AI-related drug discovery. Entities from diversified multinationals (Dassault Systems) to privately-held ones (Optibrium) are all attempting to bring AI into drug discovery. But Schrodinger’s early start, rising revenues and deep pockets allows it to pour resources into research and development (R&D) in a way that many competitors simply cannot. Analysts expect Schrodinger to spend over $200 million on R&D this year, almost 95% of its revenues.
Luke Lango wrote about this company as early as 2021. Accelerating growth and improving technologies suggest now could be an ideal time to revisit this moonshot bet.
AI’s Biotech Boost: XBI and IBB
Finally, investors seeking a big picture investment should read Eric’s latest report on the “Two Different Flavors of Biotech.” In it, he explains why both the blue-chip iShares Biotechnology ETF (IBB) and the riskier SPDR S&P Biotech ETF (XBI) are bets worth taking.
In the case of the former, more conservative pick:
Many of the biggest pharmaceutical companies in the world are paying tens of billions of dollars to snap up promising, albeit profitless, biotech companies. You could call it a biotech gold rush.
Presumably, the “crazy” prices major pharmaceutical companies are paying to acquire early-stage biotech companies aren’t crazy at all. The acquiring companies must believe that they can utilize AI to quickly convert the profitless potential of their biotech acquisitions into robust profitability.
Essentially, the IBB ETF focuses on blue-chip stocks. Eight of its top ten constituents produce profits, and its largest holdings include firms like Gilead (GILD), Regeneron (REGN) and Amgen (AMGN). On average, these firms trade at a 22.6X forward P/E ratio, barely above its ten-year average of 19.6X.
Meanwhile, the riskier SPDR S&P Biotech ETF (XBI) gives greater upside potential. As Eric also notes:
When animal spirits are running hot in the stock market, the speculative XBI portfolio outperforms the relatively conservative IBB portfolio by a wide margin.
That’s because the XBI ETF covers more speculative bets. Only one of the top ten holdings of the XBI portfolio has booked a profit during the last 12 months. And given the stock market’s recent rally, it’s no surprise that XBI has risen 30%, compared to IBB’s more muted 12%.
In either case, he believes that AI-enchanced drug discovery will help revolutionize the economics of drug discovery. Rather than pour millions of dollars into unknown cures, biotech firms may be able to virtually test these therapies first, and advance only the best candidates into human trials.
ADVERTISEMENT
The so-called experts are at it again, calling crypto investors “idiots” and Bitcoin a “hyped-up fraud.” But crypto pioneer Charlie Shrem says to ignore these people. In 2018 alone, over 100 media sources proclaimed the death of Bitcoin. It’s up 1,825% since.
Now, Charlie’s found five altcoins he thinks will soar
The Quant Edge
The bets you’ve just read rely heavily on fundamental research. Insider purchases... blockbuster drugs... AI developments... these are all factors that can change the course of a company.
However, fundamental factors aren’t always present. A lull in the biotech industry during 2016 through 2020 left few good options besides the largest firms. And insiders aren’t always buying shares of their companies for the right reasons.
As luck would have it, Luke’s latest project helps investors overcome this. In his 2nd Trillion-Dollar AI Trade summit, he explains why his system is picking out bets that are performing even better than regular breakout stocks. And the timing for this summit couldn’t have been better, because a certain change in policy is about to send certain biotech stocks soaring. And thanks to Luke’s system, he’s been able to identify six stocks that are poised to skyrocket. He put all six of these tiny companies inside a brand-new report called The 6,000% A.I. Biotech Blueprint. Find out how to access it here.
I’ll see you back here next week.
Regards,
Thomas Yeung, CFAMarkets
Analyst, InvestorPlace
Comments
Post a Comment